T1	Premise 874 1129	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
T2	Premise 781 873	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
T3	Premise 567 780	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
T4	Premise 1130 1236	However, the difference among these three groups and the 24-week optimized therapy group were significant.
T5	Premise 1237 1314	Differences were not observed in the HBeAg seroconversion between each group.
T6	Premise 1315 1487	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
T7	Claim 1488 1652	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
R1	Support Arg1:T4 Arg2:T1	
